DEPARTMENT OF ANOMALOUS PHENOMENA
DIVISION OF RESEARCH — ANOMALOUS PHYSIOLOGY SECTION
───────────────────────────────────────────────────────────────
FILE: RD-IMG-03 / RESEARCH DOSSIER — “INVISIBLE MAN” (SUBJECT: G / “GRIFFIN-TYPE”)
CLASSIFICATION: LEVEL 5 — RESTRICTED (PORTIONS REDACTED)
ACCESS: RESEARCH, MEDICAL, DIRECTORATE OVERSIGHT ONLY
LAST UPDATED: 2025-09-22
PERIOD COVERED: 1992–1999 (primary experiments); addenda 2002–2004 (replication attempts)
───────────────────────────────────────────────────────────────

EXECUTIVE SUMMARY — CONTEXT & CLAIMS

  • Between 1992–1999 Directorate field recovery operations yielded biological and physical samples plausibly linked to IMG-03 instances (epidermal fragments, anomalous protein residues, particulate dispersal patterns).

  • Research Division successfully isolated a candidate biomolecular complex (hereafter Compound A-R) showing correlation with refractive-index modulation at micro-surface layers in ex vivo assays.

  • Controlled administration in limited animal models produced reversible optical attenuation of fur/skin regions and altered thermal emissivity; subsequent refinement led to a formulation colloquially labeled “the serum” (operational name: RD-SERUM-v1).

  • A secondary antagonist compound (operational name: RD-ANTIDOTE-v1) was derived which transiently restored standard optical properties when applied systemically/topically — i.e., a crude “on/off” control of the phenotype.

  • These results enabled a series of containment/diagnostic experiments and informed the operational SOPs described in ER-IMG-03. Ethical, legal, and safety constraints halted human efficacy trials; all human “toggle” use in the field was emergency-only and remains controversial.

───────────────────────────────────────────────
I. LABORATORY NOTES — ISOLATION & CHARACTERIZATION OF COMPOUND A-R
(Lead Investigator: Dr. L. Nguyen — Anomalous Physiology)

  1. Sample provenance

  • Epidermal scrapings recovered from IMG-03-A scene (1992), partial hair fiber from IMG-03-B, and an anomalous particulate recovered in IMG-03-F (ship corridor). Samples cross-correlated for recurring anomalous protein bands via SDS-PAGE under denaturing conditions. Band constellation consistent across samples — later labeled A-R complex.

  1. Biochemical properties (summary)

  • Molecular profile: heterogeneous glycoprotein complex with lipid-anchored nanostructure signature (approx. molecular weight range: multiple peaks within 20–120 kDa). Shows high affinity for phospholipid membranes and forms lattice-like aggregates under scanning EM.

  • Optical interaction: in vitro membrane assays with A-R-coated bilayers produced measurable refractive index gradient across microscale (interferometry). When A-R lattice density reached threshold (≈ X ng/mm² — precise value redacted), light scatter decreased across 400–700 nm band within assay chamber. Thermal emissivity shifted by ~0.8–1.6°C apparent, depending on background.

  • Stability: A-R complex denatures at >56°C; stable at 4°C for archival; sensitive to proteolytic enzymes (trypsin) — however, lattice reforming observed after reconstitution in controlled ionic buffers.

  1. Hypothesis (working)

  • A-R forms a dynamic dermal lattice that locally alters surface refractive indices and causes phase-shifted scattering such that human-visible photons are refracted/redirected around tissue rather than reflected — functional invisibility. The mechanism appears to be a hybrid of structural nanoscale modulation and induced, localized EM field perturbation (see section on EM signatures).

───────────────────────────────────────────────
II. RD-SERUM-v1: FORMULATION, ADMINISTRATION, EFFECTS, & TOXICITY
(Preclinical dossier excerpts; non-proprietary wording where possible)

  1. Formulation (high level)

  • RD-SERUM-v1 = stabilized A-R emulsion + carrier (buffered lipid micelle) + delivery adjuvant (to facilitate dermal insertion). Precise reagent ratios and synthesis pathways REDACTED (Directorate order).

  1. Administration modes tested

  • Topical micro-injection (dermal intradermal grid).

  • Intravenous microbolus with liposomal targeting (attempt at systemic expression).

  • Aerosolized microdroplet — tested only in sealed chambers; significant uncontrolled dispersion risk; discontinued.

  1. Observed primary effects (animal models — ovine and rodent cohorts)

  • Onset: 5–18 minutes post-administration (topical grid) for localized visual attenuation. Systemic IV routes produced whole-body attenuation within 30–90 minutes in small cohorts.

  • Optical: attenuation persisted while lattice integrity maintained; partial translucency in low-light conditions; full visual negation in ~70% of trials under controlled illumination.

  • Thermal: reduction in infrared signature (~0.5–2°C apparent reduction).

  • Sensory side effects: vestibular disturbance in rodent models on systemic dosing (staggering), transient tachycardia, acute disorientation.

  • Behavioral: animals displayed increased startle response and, in prolonged expression (>6 hrs), self-directed biting at treated areas.

  1. Reversibility & RD-ANTIDOTE-v1

  • RD-ANTIDOTE-v1 (antagonist peptide cocktail) administered topically or IV caused dissolution of A-R lattice in vitro and restored normal optical properties within 2–12 minutes in vivo.

  • Reversibility window: robust in early-stage administration (<24 hrs). Lattices older than ~72 hrs demonstrated partial resistance — required higher antidote dosing and produced inflammatory reaction.

  1. Toxicity & failure modes

  • Dosing beyond threshold produced systemic inflammatory response syndrome (SIRS) in 2/30 ovine subjects and one mortality (multi-organ failure). Long-term expression correlated with progressive neural desynchronization (EEG anomalies in higher mammals).

  • Antidote over-administration caused rapid breakdown of lattice with release of aggregated glycoprotein fragments; fragments appear to be neuro-active in concentrated doses — observed seizure activity in rodent models.

  • Immunogenicity: A-R provoked sustained antibody response; risk of auto-immune cascade noted after repeat exposures.

  1. Ethical & legal note (internal)

  • Directorate legal counsel advised cessation of human trials pending comprehensive immunogenicity and neurotoxicity studies. Full human trials were never authorized beyond emergency containment applications.

───────────────────────────────────────────────
III. DOCTORS’ NOTES — FIELD TRIALS & EMERGENCY USE (SELECTED)
(Compiled notes: Dr. L. Nguyen, Dr. R. Salazar, Dr. M. O’Connell)

— 1999 Emergency Containment Use (Site-12B retrieval)
Dr. L. Nguyen — Entry 1999-06-17: “Administered topical RD-SERUM-v1 to recovered suspect tissue to ‘light up’ residual lattice for imaging. Serum locally induced refractive change and aided in visualizing lattice boundary under polarized laser sweep. Antidote applied after image capture. Patient (unregistered subject derived from field capture) showed acute tremor post antidote; stabilized with benzodiazepine. Recommend: stricter microdose protocols and premedicate with anti-inflammatory.”

— Field Antidote Use (Controlled)
Dr. R. Salazar — Entry 2002-03-02 (addendum): “RD-ANTIDOTE-v1 effective for rapid extraction of lattice when delivered IV at controlled rate; adverse effects manageable in sedated subjects. Note high risk when lattice older than 48 hours — fragmentation events observed. Operational use on human subject is last-resort only.”

— Long-term Follow up (Dr. M. O’Connell)
Entry 2004-11-21: “Survivors exposed to serum toggles exhibit chronic neurocognitive symptoms — attention deficits, flash hallucinations (auditory/olfactory). When toggled repeatedly, subjects develop dysphoria and increased mimicry propensity; hypothesis: toggling might dysregulate neural patterning associated with identity memory. Recommend severe restrictions on repeated on/off use.”

───────────────────────────────────────────────
IV. THEORETICAL MEMO: GRIPPIN/THE “GRIFFIN-TYPE” INTERPRETATION
(Internal white paper: “On the Personhood & Psychogenesis of IMG-03” — Author: Narrative/Neurocognitive Unit)

  1. Core proposition

  • “Griffin” (operational shorthand referencing H.G. Wells’ protagonist as analytic shorthand) describes a class of anomaly where physical optical negation is coupled to high-order social/psychological mimicry and memetic patterning. Our working model posits two interacting systems: (A) structural (A-R lattice, physical invisibility mechanics) and (B) cognitive/performative (voice mimicry, social exploitation, escalatory cruelty).

  1. Cognitive observations

  • Instances display pronounced ability to replicate recorded voices with high accuracy, anticipate human emotional responses, and weaponize intimate audio artifacts (answering machines, tapes) to create trust vectors. This suggests either (i) pre-existing human knowledge exploited via surveillance, (ii) associative learning accelerated by neurochemical alteration post-A-R exposure, or (iii) anomalous memetic amplification enabling pattern extraction from minimal cues.

  1. Personhood & agency

  • Some recovered instances (audio logs show speech, recorded hiss, mutterings) indicate complex self-narration — not mere survival drives but performance. This raises questions: is IMG-03 a human with an added capability, or does the lattice induce a separate agentive overlay? The answer alters containment approaches. If the former, rehabilitation may be possible; if the latter, lockdown and non-interactive protocols are safer.

  1. Ethical implications & memetics

  • Mimicry capability creates memetic risk; public fascination may incentivize imitation behaviors. Containment policy must include memetic suppression (redaction, press control) and monitored psychological care for survivors to prevent memetic propagation.

───────────────────────────────────────────────
V. EXPERIMENTAL LOGS & STORY-BY-STORY BEAT SUMMARY (how research intersected with field events)

  • 1992–1993 (Discovery & Baseline):

    • Field recoveries from Hall and Marvel produced initial A-R signatures. In-lab assays first demonstrated refractive index anomalies (RD note: 1994, Dr. Nguyen). No serum yet; containment relied on mechanical detection.

  • 1995 (Mimicry Case — Family Unit):

    • Cassette evidence demonstrated audio-editing/mimicry. Narratives pushed Research to look for neuro-active fragments in recovered particulates; A-R found co-localized with trace RNA sequences (non-human motif); hypothesis of lattice-neurochemical feedback formed.

  • 1996 (Maritime Event):

    • High-salt, confined environment tests prompted Research to adapt carrier micelles for RD-SERUM to maintain stability in high-ionic conditions. Lab-scale trials showed feasibility; emergency containment protocols drafted.

  • 1998 (Public Exposure):

    • Large-scale public event and compressed exposure of specimens forced accelerated antidote research. RD-ANTIDOTE-v1 passed bench trials; field readiness at Site-12B elevated.

  • 1999–2004 (Containment & Ethical Freeze):

    • Limited emergency use of RD-SERUM and RD-ANTIDOTE in Site-12B retrievals. Human toggles performed in extremis; adverse neurologic outcomes observed. Directorate placed moratorium on non-consensual human trials. Continued animal studies and improved stabilization protocols.

───────────────────────────────────────────────
VI. MEDICAL RECOMMENDATIONS & POLICY CONSIDERATIONS (RESEARCH DIVISION)

  1. Operational

  • RD-SERUM-v1 classified as Emergency Containment Agent only. Use requires Level-5 Director authorization and Medical Director on site. Antidote must be co-stocked; contingency for fragmentation events must be in place (sedation + filtration).

  • Personnel handling must be vaccinated (experimental antibody protocol developed against A-R epitopes); see immunization registry (Appendix REDACTED).

  1. Research

  • Prioritize immunogenicity mapping of A-R fragments to design safer antidote vectors. Explore non-biochemical detection (advanced LIDAR/interferometry) to reduce reliance on toggles.

  • Investigate cognitive sequelae of toggling — longitudinal psychiatric cohort recommended.

  1. Ethical/Legal

  • Maintain moratorium on voluntary human trials until neurotoxicity risk mitigated; any emergency field use must be accompanied by post-exposure long-term care funding.

  • Media suppression remains necessary to prevent memetic contagion; coordinate with Directorate Memetics Unit.

───────────────────────────────────────────────
VII. APPENDICES (brief index — full docs sealed)
A. RD-Lab raw SDS-PAGE gels & EM micrographs (Vault-7 image set).
B. Animal trial datasets (ovoid cohort n=48).
C. RD-SERUM formulation ledger (REDACTED).
D. 1999 Site-12B emergency administration report (Dr. L. Nguyen).
E. Narrative/Neurocognitive Unit white paper on “Griffin-type agency” (2001).
F. Immunization pilot protocol (Level-5 restricted).

───────────────────────────────────────────────
NOTES FROM THE DIVISION HEAD (Dr. R. Salazar) — 2025-09-22
“We cracked something. Not the myth, not the person — a mechanism. That mechanism behaves like a mirror and a voice at once. It buys you a cloak and then learns to whisper in the same accent as whatever you’ve lost. Science gave us a way to flip it; ethics made us keep our hands off the switch. Keep this file tight. The serum saves lives in the short term and breaks them in the long one. That’s the problem we can’t paper over.”

───────────────────────────────────────────────
END OF FILE — RD-IMG-03 — DO NOT DUPLICATE OR TRANSMIT OUTSIDE AUTHORIZED CHANNELS.